99 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
in $5.0 million in gross proceeds.
R&D Expenses: Research and development expenses for the full year 2023 were $6.1 million, compared to $2.7 million … expenses
Research and development - licenses acquired
General and administrative
Loss from operations
Interest income
Financing costs – warrant
8-K
ATXI
Avenue Therapeutics Inc
15 Mar 24
Other Events
7:15am
research and development and manufacturing capabilities; expectations for generating revenue or becoming profitable on a sustained basis; expectations
DEF 14C
ATXI
Avenue Therapeutics Inc
29 Jan 24
Information statement
8:00am
. We expect our research and development expenses to continue to be significant in connection with our continued investment in our drug candidates
PRE 14C
ATXI
Avenue Therapeutics Inc
17 Jan 24
Preliminary information
5:05pm
, 2022, we had an accumulated deficit of approximately $91.6 million and $80.6 million, respectively. We expect our research and development expenses
8-K
EX-99.1
kmd zbo1si1dbxe
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
idmbavt2a
24 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1:19pm
8-K
EX-99.1
52uuj ry27unxk
13 Nov 23
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
4:10pm
8-K
EX-99.2
xb8 jnyj46k07gnb
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-99.1
n3b8k 9em9wqdsnnqfsv
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
2xhs6z39
2 Nov 23
Prospectus supplement with pricing info
9:00am
8-K
EX-99.1
s1si ly7trvxcq689t
10 Aug 23
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:20pm
8-K
anz2b0ev6
21 Jul 23
Other Events
4:37pm
8-K
xewkz0iiwvdv68d7l0e
22 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:07pm